SCHEMBL3096819

SCHEMBL3096819

O=C(c1cnc(N2CCOCC2)s1)N1CCC(C(=O)O)(c2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 6/20 0.54
HTR2C P28335 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
OGA O60502 1/20 0.46
SCD O00767 2/20 0.45
GAA P10253 2/20 0.44
TET3 O43151 1/20 0.44
KMT2A Q03164 1/20 0.44
FBXL19 Q6PCT2 1/20 0.44
CXXC5 Q7LFL8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7910491 0.85 OGA (0.49) MLYCDHDAC3HDAC4HDAC1HDAC7
SCHEMBL3088924 0.78 ALDH1A1 (0.68) TET3KMT2AFBXL19CXXC5TET1
SCHEMBL3097606 0.77 TSHR (0.58) TET3KMT2AFBXL19CXXC5TET1
SCHEMBL3092940 0.75 KDM4E (0.46) TET3KMT2AFBXL19CXXC5TET1
SCHEMBL3097936 0.74 POLB (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL11387823 0.73 HTR2C (0.67) HTR2CHDAC1HDAC6GAAKDM4E
SCHEMBL31539152 0.71 OGA (0.43) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3088903 0.71 KDM4E (0.53) MLYCDHDAC3HDAC4HDAC1HDAC7
SCHEMBL3098171 0.71 KMT2A (0.51) HDAC1HDAC6TET3KMT2AFBXL19
SCHEMBL8217601 0.70 HDAC3 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 MLYCD 3878/4885HTR2C 26/4885HDAC3 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.